Correlated diffusion imaging
Tóm tắt
Prostate cancer is one of the leading causes of cancer death in the male population. Fortunately, the prognosis is excellent if detected at an early stage. Hence, the detection and localization of prostate cancer is crucial for diagnosis, as well as treatment via targeted focal therapy. New imaging techniques can potentially be invaluable tools for improving prostate cancer detection and localization. In this study, we introduce a new form of diffusion magnetic resonance imaging called correlated diffusion imaging, where the tissue being imaged is characterized by the joint correlation of diffusion signal attenuation across multiple gradient pulse strengths and timings. By taking into account signal attenuation at different water diffusion motion sensitivities, correlated diffusion imaging can provide improved delineation between cancerous tissue and healthy tissue when compared to existing diffusion imaging modalities. Quantitative evaluation using receiver operating characteristic (ROC) curve analysis, tissue class separability analysis, and visual assessment by an expert radiologist were performed to study correlated diffusion imaging for the task of prostate cancer diagnosis. These results are compared with that obtained using T2-weighted imaging and standard diffusion imaging (via the apparent diffusion coefficient (ADC)). Experimental results suggest that correlated diffusion imaging provide improved delineation between healthy and cancerous tissue and may have potential as a diagnostic tool for cancer detection and localization in the prostate gland. A new form of diffusion magnetic resonance imaging called correlated diffusion imaging (CDI) was developed for the purpose of aiding radiologists in cancer detection and localization in the prostate gland. Preliminary results show CDI shows considerable promise as a diagnostic aid for radiologists in the detection and localization of prostate cancer.
Tài liệu tham khảo
American Cancer Society: Cancer Facts & Figures 2012. 2012, Atlanta: American Cancer Society
Ren J, et al: MRI of prostate cancer antigen expression for diagnosis and lmmunotherapy. PLoS ONE. 2012, 7 (60): e38350-
Jemal A, et al: Cancer statistics. CA Cancer J Clin. 2010, 60: 277-300. 10.3322/caac.20073.
Damber J-E, et al: Prostate cancer. Lancet. 2008, 371: 1710-1721. 10.1016/S0140-6736(08)60729-1.
Jani AB, Hellman S: Early prostate cancer: clinical decision-making. Lancet. 2003, 361: 1045-1053. 10.1016/S0140-6736(03)12833-4.
Gronberg H: Prostate cancer epidemiology. Lancet. 2003, 361: 859-864. 10.1016/S0140-6736(03)12713-4.
Stenman J, et al: Prostate-specific antigen. Semin Cancer Biol. 1999, 9: 83-93. 10.1006/scbi.1998.0086.
Chou R, et al: Screening for prostate cancer - a review of the evidence for the U.S. preventive services task force. Ann Intern Med. 2011, 155 (11): 762-771. 10.7326/0003-4819-155-11-201112060-00375.
Norberg M, et al: The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology. 1997, 50: 562-566. 10.1016/S0090-4295(97)00306-3.
Beerlage HP, et al: Correlation of transrectal ultrasound, computer analysis of transrectal ultrasound and histopathology of radical prostatectomy specimen. Prostate Cancer Prostatic Dis. 2001, 4: 56-62. 10.1038/sj.pcan.4500495.
Olafsen T, et al: Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J Immunother. 2007, 30: 396-405. 10.1097/CJI.0b013e318031b53b.
Lapi SE, et al: Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer. Nucl Med. 2009, 50: 2042-2048. 10.2967/jnumed.109.066589.
Lepin EJ, et al: An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors. Eur J Nucl Med Mol Imaging. 2010, 37: 1529-1538. 10.1007/s00259-010-1433-1.
Giovacchini G, et al: PSA doubling time for prediction of 11C choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2010, 37: 1106-1116. 10.1007/s00259-010-1403-7.
Turkbey B, et al: Imaging techniques for prostate cancer: implications for focal therapy. Nat Rev Urol. 2009, 6: 191-203. 10.1038/nrurol.2009.27.
Khoo VS, et al: Comparison of MRI with CT for the radiotherapy planning of prostate cancer: a feasibility study. Br J Radiol. 1999, 72: 590-597.
Debois DF, et al: The contribution of magnetic resonance imaging to the three-dimensional treatment planning of localized prostate cancer. Int J Radiat Oncol Biol Phys. 1999, 45: 857-865. 10.1016/S0360-3016(99)00288-6.
Jackson AS, et al: Distortion-corrected T2 weighted MRI: a novel approach to prostate radiotherapy planning. Br J Radiol. 2007, 80: 926-933. 10.1259/bjr/51363812.
Choi YJ, et al: Functional MR imaging of prostate cancer. RadioGraphics. 2007, 27: 63-75. 10.1148/rg.271065078.
Koh DM, Padhani AR: Diffusion-weighted MRI: a new functional clinical technique for tumour imaging. Br J Radiol. 2006, 79: 633-635. 10.1259/bjr/29739265.
Hosseinzadeh K, Schwarz SD: Endorectal diffusion-weighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue. J Magnetic Reson Imaging. 2004, 20: 654-661. 10.1002/jmri.20159.
Woodfield CA, et al: Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. Am J Roentgenol. 2010, 194: 316-322. 10.2214/AJR.09.2651.
Turkbey B, et al: Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images?. Radiology. 2011, 258: 488-495. 10.1148/radiol.10100667.
Haider MA, et al: Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. Am J Roentgenol. 2007, 189: 323-328. 10.2214/AJR.07.2211.
Barentsz JO, et al: ESUR prostate MR guidelines. Eur Radiol. 2012, 22 (4): 746-757. 10.1007/s00330-011-2377-y.
Algaba F, Montironi R: Impact of prostate cancer multifocality on its biology and treatment. J Endourol. 2010, 24: 799-804. 10.1089/end.2009.0462.
Stejskal EO, Tanner JE: Spin diffusion measurements: spin echoes in the presence of a time-dependent field gradient. J Chem Phys. 1965, 42: 288-10.1063/1.1695690.
Le Bihan D, Breton E: Imagerie de diffusion in-vivo par resonance magnetique nucleaire. C R Acad Sci. 1985, 301: 1109-1112.
Kiricuta IC, Simplaceanu V: Tissue water content and nuclear magnetic resonance in normal and tumor tissues. Cancer Res. 1975, 35: 1164-1167.
Paran Y, et al: Water diffusion in the different microenvironments of breast cancer. NMR Biomed. 2004, 17: 170-180. 10.1002/nbm.882.
Koh DM, Collins DJ: Diffusion-weighted MRI in the body: applications and challenges in oncology. Am J Roentgenol. 2007, 188: 1622-1635. 10.2214/AJR.06.1403.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2342/13/26/prepub